The acute administration of the selective dopamine D3receptor antagonist SB‐277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats
Open Access
Abstract
We examined the effect of SB‐277011A, a selective D3receptor antagonist, on the conditioned place aversion (CPA) response associated with naloxone‐induced withdrawal from acute morphine administration in male Sprague‐Dawley rats. Morphine (5.6 mg/kg i.p.) was given, followed 4 hrs later by naloxone (0.3 mg/kg i.p.) and prior to placing the animals in one specific chamber of the test apparatus. All animals were subjected to 2 of these trials. A significant CPA occurred in animals that received an i.p. injection of vehicle 30 minutes prior to the measurement of chamber preference. The pretreatment of animals (30 minutes prior to testing) with 3 mg/kg i.p. of SB‐277011A did not significantly alter the CPA compared to animals treated with vehicle (1 ml/kg i.p. of deionized distilled water). In contrast, the acute pretreatment of animals with 6, 12 or 24 mg/kg i.p. of SB‐277011A significantly decreased the CPA compared to vehicle‐treated animals. In fact, the 12 and 24 mg/kg doses of SB‐277011A significantly increased the time spent in the chamber where animals were paired with morphine and naloxone. These results suggest that the selective antagonism of D3receptors attenuates the CPA produced by a model of naloxone‐induced withdrawal from acute morphine dependence. Synapse, 2012.Keywords
This publication has 21 references indexed in Scilit:
- Dopamine D3 receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in ratsEuropean Journal of Pharmacology, 2011
- Current perspectives on selective dopamine D3receptor antagonists as pharmacotherapeutics for addictions and related disordersAnnals of the New York Academy of Sciences, 2010
- Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonistsEuropean Neuropsychopharmacology, 2009
- The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in ratsPsychopharmacology, 2007
- The dopamine D3 receptor plays an essential role in alcohol‐seeking and relapseThe FASEB Journal, 2006
- The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidenceBrain Research Reviews, 2005
- Conditioned place aversion is a highly sensitive index of acute opioid dependence and withdrawalPsychopharmacology, 2003
- Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate CortexNeuropsychopharmacology, 2002
- Dopamine D3Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in RatsJournal of Neuroscience, 2002
- Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-AThe Journal of Pharmacology and Experimental Therapeutics, 2000